<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02766868</url>
  </required_header>
  <id_info>
    <org_study_id>RJH-2015-RefactoryALL-SCT</org_study_id>
    <nct_id>NCT02766868</nct_id>
  </id_info>
  <brief_title>Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse ALL</brief_title>
  <official_title>Sequential Intensive Chemotherapy With Reduced Intensity Conditioning Regimen in Adult Patients With Refractory and Relapse Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with refractory and relapse lymphoblastic leukemia had poor outcome even with marrow
      ablative conditioning mostly standard iv-Bu-Cy or Cy-TBI. In this study, we focus on a new
      treatment strategy with high-dose chemotherapy regimen consisting of
      fludaraibine+cytarabine+cyclophosphamide+etoposide followed by reduced intensity condiotning
      regimen consisting of fludarabine, busulfan and post-infusion cyclophophamide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients with refractory and relapse lymphoblastic leukemia will receive a high-dose
      chemotherapy regimen consisting of fludaraibine+cytarabine+ cyclophosphamide+etoposide. At
      day 7 after chemo, a bone marrow aspiration and MRD study by flow-cytometry is planned. For
      those patients with no residual blasts will undergo allogeneic stem cell transplantation with
      reduced intensity condiotning regimen consisting of 5-day fludarabine and 3-day busulfan and
      post-infusion cyclophophamide (D+3 and +4) as GVHD prophylaxis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lymphoblastic Leukemia, Acute, Adult</condition>
  <arm_group>
    <arm_group_label>FACE-Flu/Bu/Cy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FACE-Flu/Bu/Cy</intervention_name>
    <description>Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide</description>
    <arm_group_label>FACE-Flu/Bu/Cy</arm_group_label>
    <other_name>FACE-chemo-FLu-BU-CY conditioning</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients with refractory or relapse acute lymphoblastic leukemia not in
             remission after 2 cycles of induction chemotherapy early relapse (1st remission less
             than 6 months) not in remission after 1 cycle of re-induction chemotherapy multiple
             relapse

          -  age 16-60 years with inform consent

          -  no contraindication for allogeneic transplantation: active infection, allergy to
             FLu/Bu/CTX, liver and renal function damage

          -  HLA matched related (6/6), unrelated donors (8~10/10) or haplo

        Exclusion Criteria:

          -  liver function/renal function damage (over 2 X upper normal range)

          -  mental disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiong Hu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rui Jin Hospital, Shanghai JiaoTong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiong Hu</last_name>
    <phone>86-21-64370045</phone>
    <phone_ext>601818</phone_ext>
    <email>hujiong@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ling Wang</last_name>
    <phone>86-21-64370045</phone>
    <phone_ext>601818</phone_ext>
    <email>cclingjar@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Blood &amp; Marrow Transplantation Center, RuiJin Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Wang</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>601818</phone_ext>
      <email>cclingjar@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jiong HU</investigator_full_name>
    <investigator_title>Head, Blood and Marrow Transplantation Program</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

